Bispecific Immunomodulatory Antibodies for Cancer Immunotherapy
Open Access
- 9 June 2021
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 27 (20) , 5457-5464
Abstract
The recent advances in the field of immuno-oncology have dramatically changed the therapeutic strategy against advanced malignancies. Bispecific antibody-based immunotherapies have gained momentum in preclinical and clinical investigations following the regulatory approval of the T cell–redirecting antibody blinatumomab. In this review, we focus on emerging and novel mechanisms of action of bispecific antibodies interacting with immune cells with at least one of their arms to regulate the activity of the immune system by redirecting and/or reactivating effector cells toward tumor cells. These molecules, here referred to as bispecific immunomodulatory antibodies, have the potential to improve clinical efficacy and safety profile and are envisioned as a second wave of cancer immunotherapies. Currently, there are more than 50 bispecific antibodies under clinical development for a range of indications, with promising signs of therapeutic activity. We also discuss two approaches for in vivo secretion, direct gene delivery, and infusion of ex vivo gene-modified cells, which may become instrumental for the clinical application of next-generation bispecific immunomodulatory antibodies.Keywords
Funding Information
- Carlos III Health Institute (PI20/01030)
- Spanish Ministry of Science and Innovation (SAF2017–89437-P, RTC-2017–5944–1)
- CRIS Cancer Foundation (FCRIS-IFI-2018)
- Spanish Association Against Cancer (19084)
- Spanish Ministry of Science and Innovation (PRE2018–083445)
This publication has 81 references indexed in Scilit:
- Engineering human cells for in vivo secretion of antibody and non-antibody therapeutic proteinsCurrent Opinion in Biotechnology, 2011
- Effective Elimination of Acute Myeloid Leukemic Cells by Recombinant Bispecific Antibody Derivatives Directed Against CD33 and CD16Journal of Immunotherapy, 2010
- CatumaxomabmAbs, 2010
- CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid PhagocytosisCell, 2009
- Treatment of Malignant Pleural Effusion With the Trifunctional Antibody Catumaxomab (Removab) (Anti-EpCAM×Anti-CD3)Journal of Immunotherapy, 2009
- Antibodies and gene therapy: teaching old ‘magic bullets’ new tricksTrends in Immunology, 2004
- Integrin-associated protein (CD47) and its ligandsTrends in Cell Biology, 2001
- Re‐targeting of human lymphocytes expressing the T‐cell receptor gamma/delta to ovarian carcinoma cells by the use of bispecific monoclonal antibodiesInternational Journal of Cancer, 1989
- Systemic Reaction to the Anti–T-Cell Monoclonal Antibody OKT3 in Relation to Serum Levels of Tumor Necrosis Factor and Interferon-αNew England Journal of Medicine, 1989
- Hybrid antibodies can target sites for attack by T cellsNature, 1985